About: Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines
Creator	Du, Lanying He, Yuxian Jiang, Shibo Zheng, Bo-Jian Zhou, Yusen Yuen, Kwok-Yung Huang, Jian-Dong Ng, Fai Ma, Selene Wang, Yijia Zhang, Haojie Wong, Charlotte Wu, Sharon
Source	Elsevier; Medline; PMC
abstract	Abstract Development of an effective vaccine for severe acute respiratory syndrome (SARS) remains to be a priority to prevent possible re-emergence of SARS coronavirus (SARS-CoV). We previously demonstrated that the receptor-binding domain (RBD) of SARS-CoV S protein is a major target of neutralizing antibodies. This suggests that the RBD may serve as an ideal vaccine candidate. Recombinant adeno-associated virus (rAAV) has been proven to be an effective system for gene delivery and vaccine development. In this study, a novel vaccine against SARS-CoV was developed based on the rAAV delivery system. The gene encoding RBD was cloned into a pAAV-IRES-hrGFP plasmid. The immunogenicity induced by the resulting recombinant RBD-rAAV was evaluated in BALB/c mice. The results demonstrated that (1) a single dose of RBD-rAAV vaccination could induce sufficient neutralizing antibody against SARS-CoV infection; (2) two more repeated doses of the vaccination boosted the neutralizing antibody to about 5 times of the level achieved by a single dose of the immunization and (3) the level of the antibody continued to increase for the entire duration of the experiment of 5.5 months. These results suggested that RBD-rAAV is a promising SARS candidate vaccine.
has issue date	2006-09-15(xsd:dateTime)
bibo:doi	10.1016/j.virol.2006.03.049
bibo:pmid	16793110
has license	els-covid
sha1sum (hex)	4f737481c074112fffd66bb6048fb46931406baf
schema:url	https://doi.org/10.1016/j.virol.2006.03.049
resource representing a document's title	Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines
has PubMed Central identifier	PMC7111904
has PubMed identifier	16793110
schema:publication	Virology
resource representing a document's body	covid:4f737481c074112fffd66bb6048fb46931406baf#body_text
is schema:about of	named entity 'antibody' named entity 'evaluated' named entity 'demonstrated' named entity 'demonstrated' named entity 'remains' named entity 'vaccine' named entity 'IMMUNOGENICITY' named entity 'IRES' named entity 'RESULTING' named entity 'BASED' named entity 'THESE' named entity 'RAAV' named entity 'VACCINATION' named entity 'RBD' named entity 'IMMUNIZATION' named entity 'A MAJOR' named entity 'SARS CORONAVIRUS' named entity '283' named entity 'INDUCED' named entity 'DEMONSTRATED' named entity 'TARGET' named entity 'VACCINE' named entity 'NEUTRALIZING ANTIBODIES' named entity 'LEVEL ACHIEVED' named entity 'SINGLE' named entity 'EFFECTIVE' named entity 'S PROTEIN' named entity 'DEVELOPMENT' named entity 'POSSIBLE' named entity 'RECOMBINANT ADENO-ASSOCIATED VIRUS' named entity 'ENCODING' named entity 'SYSTEM' named entity 'DOMAIN' named entity 'RECEPTOR' named entity 'PROTEIN ' named entity 'BINDING' named entity 'DEVELOPING' named entity 'VACCINES' named entity 'ELICITS' named entity 'RECOMBINANT ADENO-ASSOCIATED VIRUS' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS' named entity 'TO INCREASE' named entity 'NEUTRALIZING ANTIBODY' named entity 'DOMAIN' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'DOSES' named entity '5.5' named entity 'VACCINE CANDIDATE' named entity 'PROVEN' named entity 'ENTIRE' named entity 'S PROTEIN' named entity 'SUFFICIENT' named entity 'IDEAL' named entity 'TO PREVENT' named entity 'GENE DELIVERY' named entity 'DOSE' named entity 'DELIVERY SYSTEM' named entity 'PROTEIN ' named entity 'RECOMBINANT' named entity 'GENE' named entity 'IS A' named entity 'INDUCE' named entity 'ANTIBODY' named entity 'STUDY' named entity 'SARS' named entity 'DURATION' named entity 'LEVEL' named entity 'CANDIDATE' named entity 'EMERGENCE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software